Plasmid delivery
Temporary genetic instructions without a viral vector and without permanent DNA editing.
FST-344A plasmid gene therapy for strength, body composition, and long-term vitality.
FST-344
Follistatin
A plasmid gene therapy for strength, body composition, and long-term vitality.
Follistatin is designed to temporarily increase production of the follistatin protein, reducing biological brakes connected to muscle mass, inflammation, and physical performance.
Non-viralClinician-guidedAnnual durationNo permanent change
+2 lbfat-free mass
-0.81%body fat
12 yrsepigenetic age in older patients
How it works
A temporary signal to unlock biological output.
The therapy uses a circular plasmid with instructions for cells to produce follistatin for a limited period.
Follistatin binds myostatin and activin, two regulators that can limit muscle development, recovery, and inflammatory balance.
The plasmid does not integrate into chromosomes. The intent is temporary expression, guided by clinical evaluation and Livvay ecosystem data.
Muscle brake inhibition
Follistatin reduces the action of myostatin and activin, creating room for stronger body composition.
Continuous monitoring
Labs, signals, and routine flow into the app to track response, recovery, and next adjustments.
Anticipated benefits
The target is not only muscle. It is biological margin.
01
Increase lean mass
Participants observed an average 2 lb gain in fat-free mass during early follow-up.
02
Reduce body fat
Reference data shows an average 0.81% body fat reduction at 3 months.
03
Lower epigenetic age
In older patients, the public reference metric showed a 12-year reduction in epigenetic age.
04
Improve vitality
Stronger body composition may support training, recovery, physical confidence, and an active routine.
How to start
From intent to follow-up, without dropping context.
Enter through the app
Start in Livvay App to create your timeline, register goals, and open contact with the team.
Complete evaluation
The team guides labs, history, and clinical criteria before any therapy decision.
Receive therapy
Application happens at a licensed partner clinic through a subcutaneous injection and local guidance.
Track response
The Livvay ecosystem follows signals, routine, and outcomes to turn biological response into next steps.
3-month outcomes
Measured signals, not empty promise.
Public reference data for FST-344. Results vary by person and depend on medical evaluation, routine, labs, and adherence.
What to expect
An annual response, tracked in phases.
Onset
First physical signals and changes in body perception.
Boost
Incremental changes in composition, training, and recovery.
Maintain
Consistent effects while routine and monitoring support response.
Review
Clinical reassessment to decide next steps with real data.
Windows are estimates. Individual response may differ.
Our approach vs traditional
Livvay plasmid therapy compared with traditional viral gene therapy.
Criterion
Our plasmid approach
Traditional viral gene therapy
Duration
Our plasmid approachApproximately 1 year
Traditional viral gene therapyCan be permanent or difficult to modulate
Vector
Our plasmid approachNon-viral plasmid
Traditional viral gene therapyViral vector such as AAV
Application
Our plasmid approachSingle subcutaneous injection
Traditional viral gene therapyAdministration can be more complex
Storage
Our plasmid approachSimpler clinical operation
Traditional viral gene therapyMay require extreme cold chain
Philosophy
Our plasmid approachGuided and scalable adoption
Traditional viral gene therapyTraditionally focused on rare diseases
Partner clinic
Guided application in Central America.
Therapy is performed by a homologated and licensed Livvay partner clinic. Optimus patients receive concierge, travel orientation, and follow-up before, during, and after application.
Start through the appFAQ
Important questions before deciding.
Does Follistatin permanently change my DNA?
That is not the intent. The therapy uses a plasmid that does not integrate into chromosomes and seeks temporary expression.
How is it administered?
Application is subcutaneous, in a clinical setting, by a licensed professional after individual evaluation.
How long does it last?
The expected window is approximately 12 months, with individual variation and required follow-up.
Who should not receive it?
People who are pregnant or planning pregnancy in the next year should not receive therapy. Eligibility depends on medical evaluation.
How will I know it worked?
We track body composition, labs, app signals, performance, recovery, and clinical evaluation.
Is this a promise of results?
No. The numbers are public references and may vary. Decisions should be made with a physician and proper monitoring.
* Individual results vary. Follistatin should only be considered after medical evaluation. Livvay organizes monitoring, data, and concierge support, and does not replace individual clinical decisions.